Amplitude Vascular Systems (AVS) is a medical device company based in Boston, MA, focused on safely and effectively treating severely calcified arterial disease. AVS is backed by global investors including BioStar Capital and Cue Growth Partners to develop their innovative Pulse IVL System that has recently received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its pivotal trial.

Angie Volk, VP of Business Development, and Sean Gilligan, COO of AVS, join this episode to share about their team’s mission and how they are bringing this exciting technology to market. With Johnson & Johnson’s $13.3B acquisition earlier this year of Shockwave Medical, the IVL space is showing that it is currently one of the hottest spaces in medtech. We discuss how AVS’s Pulse IVL System is being designed to easily deliver therapy across complex calcified lesions and reduce overall procedural costs, making it hugely attractive to potential future acquirers.

As former Boston Scientific colleagues, Angie and Sean have extensive industry experience including unique insights of building a winning culture, and they are leveraging these learnings and their network to efficiently navigate their solution to patients across the globe. With two medtech veterans, this is a conversation brimming with helpful tips for any would-be entrepreneur that is sure to leave you informed and inspired.

The Future Health Index (FHI) survey conducted by Philips, a global leader in health technology, explores the challenges within healthcare systems and the innovative solutions being used to address them. From the survey findings, the recently released ninth annual report - 'Better Care for More People', demonstrates the pressures of staffing shortages and burnout on clinicians, and their ability to deliver timely, high-quality care to patients.

Jeff DiLullo, Chief Region Leader for Philips North America, joins this episode to discuss the findings and share how Philips is utilizing collaborative innovation to address the challenges. Jeff highlights the investments that healthcare leaders are making to help ease the burden on staff, such as automation and artificial intelligence, and those that are having an impact on increasing access and health equity such as virtual care.

Technology adoption is no longer a choice, but an imperative that leaders like Jeff are working with the community to bring solutions to where they are needed most. From AI to telehealth and virtual care, this conversation is a calling card to those who want to work together to foster innovation. Listen in for some wonderful takeaways from Jeff, and be sure to check out the Future Health Index 2024 Report so you can be informed and inspired.

Founded in 2017, XCath is a dynamic startup at the cutting edge of revolutionary medical robotics, nanorobotics and materials science. The company develops next-generation endovascular robotic systems and steerable guidewires to treat life-threatening conditions like cerebrovascular disorders.

With strategically located campuses in Houston, Texas – home to the world's largest medical center – and Pangyo, South Korea, often referred to as the Silicon Valley of Korea, XCath is committed to bringing its innovative solutions to patients around the world. CEO Eduardo Fonseca joins this episode to share how their family of engineers is making this a reality, with a value driven culture, and space-edge approach.

After recently performing the world’s first public telerobotic mechanical thrombectomy at Abu Dhabi Global Healthcare Week, it’s clear that the XCath team is helping pave the way for widescale implementation of robotic surgical tools. Eduardo outlines how the team is building on this momentous landmark to tackle the eye-watering statistics associated with stroke, a conversation that is sure to leave you informed and inspired.